NMDA inhibitors (University of Central Florida/UCF Office of Research & Commercialization)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameNMDA inhibitors (University of Central Florida/UCF Office of Research & Commercialization)

Drug Alias Nameanthraquinone and anthracene tetraamine derivatives (University of Central Florida/UCF Office of Research & Commercialization)polyamine conjugates (University of Central Florida/UCF Office of Research & Commercialization)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionGlutamate [NMDA] receptor antagonists

TargetsGlutamate [NMDA] receptor

Therapy Area/IndicationsNerve Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity of Central Florida

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity of Central Florida Office of Research and Commercialization University of Central Florida

Active IndicationsN/A

Inactive IndicationsNerve Degeneration

Other Information

ATC CodeN/A